Those of us who have enjoyed Organo Gold were already aware of the immense health benefits it offers, but now we have some independent scientific research to back us up. Two new studies published in the Annals of Internal Medicine show a link between moderate coffee drinkers and a reduced risk from diseases such as heart disease and stroke.
The studies examined 185,000 Americans and found they saw increased health benefits regardless of whether they drank caffeinated or decaffeinated coffee. It didn’t matter whether the Americans had Latino, Japanese, or African heritage either; they all indicated a lesser risk for heart disease, cancer, stroke, diabetes and kidney disease.
“Seeing a similar pattern across different populations gives stronger biological backing to the argument that coffee is good for you whether you are white, African-American, Latino or Asian,” lead author and UCLA Associate Professor of Meicine Veronica W. Setiawan said in a prepared statement.
The American Sample group regularly reported their coffee drinking habits to the researchers over a period of five years. Setiawan and her team were pleased with the results. “We cannot say drinking coffee will prolong your life, but we see an association,” she said.
A similar European study also surveyed 520,000 people across ten countries and found similar results. The researchers realized their study wasn’t without limitations, and they separated other factors such as smokers from the study as well. To say this study bodes well for those who enjoy their morning cup of Joe is an understatement.
Organo Gold has always been dedicated to delivering only the best cup of coffee to everyone. Moreover, each cup of their coffee has a host of health benefits without sacrificing on the original taste that everyone loves so well. We at Organo Gold look at this study and realize these researchers are simply waking up to something we have known all along!
Amicus Therapeutics is a biotechnological company recognized globally for their dedication towards the treatment of orphan diseases. The company has been at the forefront of research and treatment of a range of devastating rare diseases.
Amicus Therapeutics was founded in February 2002 and is based in Cranbury, New Jersey. The company is headed by John Crowley, who is the CEO and Chairman of the board. Other key figures include Bradley Campbell, who is the Chief Operations Officer, and William Baird, who is the Chief Finance Officer. Amicus Therapeutics is a publicly traded company under the brand NASDAQ. The company has been on the stock exchange since 2007 after a planned IPO.
Amicus mainly focuses on rare and orphan diseases (http://www.phillypurge.com/2017/08/02/amicus-therapeutics-the-fight-against-the-rare-diseases/). The Chaperone-Advanced Replacement Therapy, otherwise referred to as CHART is the main basis of the company’s product development. Amicus has put an emphasis on enzyme replacement therapies (ERTs). The company’s efforts have earned them accolades. In 2014, Amicus was recognized as the company with the broadest portfolio in terms of small molecule pharmacological chaperones in the entire pharmaceutical industry.
Although they had no marketed products by February 2014, some of the most notable developments from Amicus Therapeutics include migalastat, otherwise known as Galafold. Galafold is a pharmacological chaperone treatment which is aimed at stabilizing endogenous mutant alpha-galactosidase for the treatment of Fabry disease.
Amicus Therapeutics has no manufacturing capabilities and therefore relies on contract manufacturing (WeeklyOpinion). Additionally, the company collaborates with other like-minded firms to come up with treatments for complex diseases. One of its most notable collaborations was with GlaxoSmithKline and JCR Pharmaceutical. The collaboration which lasted from 2010 to 2013 was aimed at investigating co-formulation with recombinant alpha-galactosidase.
It is worth noting that in 2008, the company expanded its activities from its single location in New Jersey to a second research facility in San Diego. Additionally, Amicus got a big financial boost, when they received a US$500,000 grant in 2010 from the Michael J. Fox Foundation. The grant was aimed at supporting studies conducted by Amicus in collaboration with the David Geffen School of Medicine.
In 2013, Amicus went a step further and acquired CallidusBiopharma, which was one of their competitors. The acquisition granted Amicus Therapeutics intellectual and material property for the treatment of Pompe disease.
Alexandre Gama is a Brazilian advertising entrepreneur. He is a very skilled businessman with creativity and professionalism in both Advertising and Publicity. There are about 20 largest advertising agencies in Brazil, and among them is Neogama, an agency that Gama founded in 1999 and is currently its CEO and CCO.
Alexandre Gama graduated from Fundação Armando Alvares Penteado (FAAP), with a degree in Publicity and Advertising. The Brazil communication industry felt his presence when he started representing it after he joined ABAP. Since then, Gama has worked with other companies like BBH, DM9, among others. It is when he was the CEO of BBH that Gama became the first Brazilian to be on the leader board of global communication agencies. In 2002, Alexandre associated the two companies; Neogama and BBM, the London branch. In 2016, however, after 14 years of activity, Gama cut off the BBM network and renamed it Neogama. He showed a lot of dedication to the success of the company and put both his heart and hard work into it.
His career has had waves of successes. He has received an astounding number of awards over the years, among which are the most prestigious in Brazil. He was elected Officer of Agency of the Year, in 2006; and he received a prize for being the entrepreneur of the year, as well as a successful manager of the communications industry in 2007. Between 2009 and 2017, he has received several other awards like the prestigious Golden Lion award, which he has been accorded more than once.
If it were not for leaders like Matthew Autterson, America would not be recovering from the past damage that Pres. Obama has cost. FAB holds that Matthew Autterson is quite an asset to have in the Greater Denver Area and that he is its greatest weapon in the fight for reforming biotechnology education. What is interesting to note is that both Matthew Autterson and his wife have been working very hard in there six months in office and have, so far, kept several of the promises they made to make it in this year alone. The level of progress is astounding and only shows potential.
It appears, after all, that Matthew Autterson and his team were people of their word and intended to do just what they said when they ran for leadership roles. This is exceptionally rare to see among any biotech leader, but let it serve as a lesson to all who are running for rank: Do exactly what you promised to do, and do not lie as a way to power, for you will be found out. Instead, go the honest route and work hard, and your reputation will more than speak for itself in the long run – as it has done so for CNS Biosciences President Matthew Autterson and his team. Pres. Matthew Autterson and his crew are not alone as they also hold other top candidates in the offices surrounding them, men and women of solid conservative values who only care about the good of this country and not merely their wallets.
This makes all the difference, so keep it in mind: With such leaders behind the science arena, there is no doubt that America can change for the better. Let us keep hoping and praying. Let us support as needed and make the change. God bless America. Peace and justice to all Americans. The educational biotech arena has an entire future ahead of it, and this is only the beginning: Will you lead the change?
Matthew Autterson is a top reformer and biotech specialist. As Board Member under FAB, he has more than his share of challenges but faces them willingly. He knows, after all, what he signed up for. He has also promised to do more this year that has ever been done recently to reform the biosystem sector in Colorado and has been no less ahead in the fight than others.
The Mexican media industry hosts some of the most influential media houses in the world. Many companies have come up, and content in areas of news and entertainment has also improved. Gone are the days when the citizens were treated to a single media outlet owned by the government. With contributions of top personalities like Alfonso de Angoitia Noriega, the industry is headed in the right direction. Here are a few of the top companies in the sector.
Grupo Salinas is another top media company in Mexico with several local television channels. They include Azteca 7 and Azteca Trece. The Mexico City-based firm owns a few pay television channels that include adn40 and a+.
Grupo ACIR has graced the Mexican Media scenes since the year 1960. Its main focus has always been in the radio operations. It owns several radio stations with a few being online. These stations include Azul, City, Radio Disney, Amor, and radio Felicidad.
About Alfonso de Angoitia Noriega
Alfonso de Angoitia Noriega started working for Grupo Televisa as the CFO. His impeccable performance led him to his current position of the senior VP of the firm. Alfonso de Angoitia Noriega also sits on the board of directors of the company.
Before joining Grupo Televisa, Alfonso Angoitia Noriega worked for the White & Case LLP. in New York. His other engagements include being a director of Bolsa Mexicana de Valores.
NuoDB gives you the power to make optimizations without having to worry about any disk limitations. It also lets you preserve reliable support for SQL database and user-based security models. NuoDB lets you operate in your environment of choice, such as on-premises, in containers, or in a hybrid cloud. Messages between NuoDB processes at also always automatically encrypted for extra security.
With NuoDB, you can maximize all o your resources across data centers within close- proximity and even minimize client and application latencies. Its in-memory caches will even automatically adjust sot that you an get optimal workload performance and ass or remove compute power.
NuoDB is capable of withstanding failure at every level without the risk of bringing down your application. You can also easily migrate application code that is already in pace using in-database processing in order to achieve better performance.
NuoDB is focused on delivering a cloud database that is not only more intelligent, but that can also easily adapt to the ever-changing environment. NuoDB combines elasticity, stability, and simplicity that cloud applications require and can keep up to the toughest and most rigorous demands of the modern day world. NuoDB gives you the power that you can rely on.
NouDB is a cloud technology that divides the elements of data into software objects known as atoms. This gives support to the elasticity of the cloud and at the same time ensure that data objects are properly stored and well maintained. Also, the technology of NouDB supports MVCC (Multi-Version Concurrency Control), which helps with the detection of data deadlocks and offer solutions to access conflicts. Additionally, the design of the NouDB’s cloud database is unique in that it can employ message-oriented and object-oriented elements. These elements can be distributed using computing methodologies and peer-to-peer communication format.
The developer and marketer of NouDB technology is NouDB Inc., which also act as the vendor of the technology. NouDB Inc. was founded in 2008 as NimbusDB. Later on, NouDB 1.0 software was released in 2013 and a new series is currently in the market, which is NouDB 2.0.3. The consumers of NouBD software like it because it is flexible and has a scalable database foundation. It helps users to keep up with the pace and demand of the growing business environment. Perhaps, it is one of the most cost-effective SQL databases that can help consumers expand their business activities. It is also easy to migrate most of the applications to the cloud while using NouDB technology.
The oil industry is one of the largest industries in the world. They have a global presence and their services are used by most modernized countries. One of best-known companies in the oil industry is Nabors Industries, Ltd.
Nabors Industries was founded in 1968. They are an oil, natural gas, and geothermal drilling company. They own and operate the largest land-based drilling rig fleet in the world. According to 2008 numbers, the company employs almost 27,000 employees all over the world.
The CEO of Nabors Industries is Anthony “Tony” Petrello. He has been at the head of the company since 2011. His credentials are stellar starting with his educational background. He received both his B.S. and M.S. degrees in Mathematics from Yale University. He then went on to earn a J.D. from Harvard Law School. After his graduation from Harvard, he spent thirteen years working for a law firm.
Tony Petrello has been highly successful in his career. In addition to his work duties, he offers his time to the Texas Children’s Hospital. He is on the board there and spends a lot of time researching and advocating for neurological disorders. The Texas Children’s Hospital is home to the Jan and Dan Duncan Neurological Research Institute.
Tony Petrello and his wife are large donors to the Texas Children’s Hospital. Eight years ago, their daughter was born at 24 weeks. She weighed just 20 ounces at birth. There were some complications and it was determined that their baby had cerebral palsy. Their daughter did not progress and develop like other children, and she spends a good amount of time at the Texas Children’s Hospital.
Tony Petrello and his wife Cynthia are determined to find a cure and they donate their time and their money to that cause. The Jan and Dan Duncan Neurological Research Institute is doing great things, and the Petrello’s want to make sure those good things continue for a long time to come.